Correlation analysis of second primary malignancies in patients with glioma

doi:10.19854/j.cnki.1008-2425.2024.04.0002

Abstract

Abstract: Objective To analyze the occurrence of second primary malignancies (SPM) in patients with glioma and identify their risk factors. Methods Cases of glioma patients diagnosed from January 2000 to December 2021 were collected from the Surveillance,Epidemiology,and End Results (SEER) database.A retrospective analysis was performed on patients' demographic characteristics,clinical features,and SPM occurrence,using univariate and multivariate Cox regression analysis to identify risk factors. Results A total of 87,889 glioma patients were screened from the SEER database,with 1,043 developing SPM.The median overall survival (OS) for patients with SPM was 105.0 months.The most common sites for SPMs were the breast (34.08%),lung and bronchi (11.27%),and thyroid (10.99%).Multivariate Cox regression analysis showed that age (≥65 years:HR=3.047,95% CI:2.570~3.613,P＜0.001),pathology (glioblastoma:HR=2.091,95% CI:1.793~2.438,P＜0.001),and radiotherapy (HR=1.489,95% CI:1.276~1.736,P＜0.001) were independent risk factors for the occurrence of SPM. Conclusion Breast,lung and bronchi,and thyroid are the most common sites of SPM in glioma patients.Age,pathology,and radiotherapy are significant risk factors for SPM occurrence.Identifying these risk factors can guide personalized follow-up and screening for SPM in glioma patients.

Key words: Glioma, Second primary malignancy, SEER database, Risk factors

摘要： 目的分析脑胶质瘤患者继发第二原发恶性肿瘤(second primary malignancy,SPM)的发生情况及其危险因素。方法收集2000年1月至2021年12月监测、流行病学和结果(surveillance,epidemiology,and end results,SEER)数据库中诊断为脑胶质瘤患者的病例资料,回顾性分析患者的人口学特征、临床特征与SPM发生情况,采用单因素、多因素Cox风险回归分析其危险因素。结果从SEER数据库中共筛选出87889例脑胶质瘤患者,其中发生SPM患者为1043例。发生SPM患者中位总生存时间(overall survival,OS)为105.0个月。主要部位为乳腺(34.08%),肺和支气管(11.27%)以及甲状腺(10.99%)。多因素Cox回归显示,年龄(≥65岁:HR=3.047,95%CI:2.570~3.613,P＜0.001)、病理(胶质母细胞瘤:HR=2.091,95%CI:1.7930~2.438,P＜0.001)和放疗(HR=1.489,95%CI:1.276~1.736,P＜0.001)是影响SPM发生的独立危险因素。结论乳腺、肺和支气管和甲状腺是脑胶质瘤患者SPM最常见的发生部位,年龄、病理和放疗是SPM发生的重要危险因素,这些危险因素的确定能够指导脑脑胶质瘤患者的个性化随访及SPM的筛查。

关键词: 脑胶质瘤, 第二原发肿瘤, SEER数据库, 危险因素

CLC Number:

R739.41

Niu Wanxiang, Mu Maolin, Zhang Hongwei, Ji Ying, Cheng Chuandong. Correlation analysis of second primary malignancies in patients with glioma[J]. Chinese Journal of Stereotactic and Functional Neurosurgery, 2024, 37(4): 199-204.

牛万祥, 慕茂林, 张宏伟, 计颖, 程传东. 脑胶质瘤患者继发第二原发恶性肿瘤的相关分析[J]. 立体定向和功能性神经外科杂志, 2024, 37(4): 199-204.

References

[1] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209~249.
[2] Cao W,Chen HD,Yu YW,et al.Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020[J].Chin Med J (Engl),2021,134(7):783~791.
[3] Ohgaki H,Kleihues P.Population-based studies on incidence,survival rates,and genetic alterations in astrocytic and oligodendroglial gliomas[J].J Neuropathol Exp Neurol,2005,64(6):479~489.
[4] Bleeker FE,Molenaar RJ,Leenstra S.Recent advances in the molecular understanding of glioblastoma[J].J Neurooncol,2012,108(1):11~27.
[5] Sadowski K,Jaždžewska A,Kozłowski J,et al.Revolutionizing glioblastoma treatment:A comprehensive overview of modern therapeutic approaches[J].Int J Mol Sci,2024,25(11):5774.
[6] Warren S .Multiple primary malignant tumors:a survey of the literature and a statistical study[J].Gastroenterology,1932,93(4):779.
[7] Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7~30.
[8] Li X,Li Y,Cao Y,et al.Risk of subsequent cancer among pediatric,adult and elderly patients following a primary diagnosis of glioblastoma multiforme:a population-based study of the SEER database[J].Int J Neurosci,2017,127(11):1005~1011.
[9] Wang W.Increased incidence of second primary malignancy in patients with malignant astrocytoma:a population-based study[J].Biosci Rep,2019,39(6):BSR20181968.
[10] Jia H,Li Q,Yuan J,Sun X,Wu Z.Second primary malignancies in patients with colorectal cancer:A population-based analysis[J].Oncologist,2020,25(4):e644~e650.
[11] 李晓多,杨峤,张春高,等.原发性腹膜癌继发第二原发恶性肿瘤的相关分析[J].重庆医学,2022,51(6):995~999.
[12] Han W,Wang S,Su L,et al.Prognostic analysis of lung squamous cell carcinoma patients with second primary malignancies:a SEER database study[J].Front Oncol,2024,14:1294383.
[13] Aldape K,Zadeh G,Mansouri S,et al.Glioblastoma:pathology,molecular mechanisms and markers[J].Acta Neuropathol,2015,129(6):829~848.
[14] Li X,Zhao L,Chen C,et al.Can EGFR be a therapeutic target in breast cancer[J] ?Biochim Biophys Acta Rev Cancer,2022,1877(5):188789.
[15] Passaro A,Jänne PA,Mok T,et al.Overcoming therapy resistance in EGFR-mutant lung cancer[J].Nat Cancer,2021,2(4):377~391.
[16] Abe I,Lam AK.Anaplastic thyroid carcinoma:current issues in genomics and therapeutics[J].Curr Oncol Rep,2021,23(3):31.
[17] Hiddinga BI,Pauwels P,Janssens A,et al.O6-Methylguanine-DNA methyltransferase (MGMT):A drugable target in lung cancer[J].Lung Cancer,2017,107:91~99.
[18] Müller D,Györffy B.DNA methylation-based diagnostic,prognostic,and predictive biomarkers in colorectal cancer[J].Biochim Biophys Acta Rev Cancer,2022,1877(3):188722.
[19] Bai P,Fan T,Sun G,et al.The dual role of DNA repair protein MGMT in cancer prevention and treatment[J].DNA Repair (Amst),2023,123:103449.
[20] Wu M,Huang M,He C,et al.Risk of second primary malignancies based on the histological subtypes of colorectal cancer[J].Front Oncol,2021,11:650937.
[21] Chen M,Pan X,Wang H,et al.The risk and latency evaluation of secondary primary malignancies of cervical cancer patients who received radiotherapy:A study based on the SEER database[J].Front Oncol,2023,12:1054436.
[22] Huang H,Li Z,Huang Z,et al.Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients:a population-based analysis[J].Front Oncol,2023,13:1076997.
[23] Li J,Peng F,Huang H,et al.Trends in the risk of second primary malignances after non-Hodgkin's lymphoma[J].Am J Cancer Res,2022,12(6):2863~2875.
[24] Huang K,Xu L,Jia M,et al.Second primary malignancies in cervical cancer and endometrial cancer survivors:a population-based analysis[J].Aging (Albany NY),2022,14(9):3836~3855.